Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Taysha Gene Therapies (TSHA) announced a $50 million strategic investment from Astellas Pharma to support the development of TSHA-120 for giant axonal neuropathy (GAN) and TSHA-102 for Rett syndrome. This investment, alongside a recent public offering that raised $28 million, extends the company's cash runway into Q1 2024. Taysha will provide a regulatory update on TSHA-120 in January 2023 and expects preliminary clinical data for TSHA-102 in H1 2023. For Q3 2022, R&D expenses were $16.4 million, with a net loss of $26.3 million, showing significant cost reductions compared to the previous year.
- Astellas Pharma's $50 million investment strengthens Taysha's financial position and validates its development programs.
- Significant reduction in R&D expenses from $39.5 million in Q3 2021 to $16.4 million in Q3 2022, indicating improved cost management.
- Net loss decreased from $51.2 million in Q3 2021 to $26.3 million in Q3 2022, reflecting better financial health.
- Despite reduced losses, the company still reported a significant net loss of $26.3 million for Q3 2022.
- Ongoing dependency on external funding, as evident from reliance on Astellas and public offerings for capital.
Proceeds from follow-on offering along with Astellas strategic investment extends cash runway into first quarter of 2024
Type B end-of-Phase 2 meeting with FDA for TSHA-120 in GAN scheduled for December 13, 2022
Preliminary clinical safety and efficacy data for TSHA-102 from the first cohort of adult patients with Rett syndrome and initiation of female pediatric study expected in first half of 2023
Conference call and live webcast today at 8:00 AM Eastern Time
DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
“The strategic investment from Astellas and the successfully completed public follow-on offering have strengthened our balance sheet and extended our cash runway into the first quarter of 2024. The partnership with Astellas underscores the therapeutic and market opportunity of our two lead clinical programs in GAN and Rett syndrome. Importantly, this strategic investment further validates our platform and our scientific approach of combining established gene therapy technology with innovative targeted payload design,” said RA Session II, President, Founder and CEO of Taysha. “In 2023, we expect to provide an update on the regulatory pathway for TSHA-120 in GAN in January following our Type B end-of-Phase 2 meeting with the FDA. In addition, we intend to disclose preliminary clinical data for TSHA-102 from the first cohort of adult patients with Rett syndrome and initiate a Phase 1/2 trial for TSHA-102 in female pediatric patients with Rett syndrome in the first half of 2023.”
Recent Corporate Highlights
Strategic investment from Astellas Pharma validates Taysha’s scientific approach and capabilities as well as reinforces therapeutic and market opportunity of two lead programs
Astellas to invest a total of
- An exclusive option to obtain an exclusive license for worldwide development, manufacturing and commercial rights to:
- TSHA-120 in GAN for a period of time after receipt of the formal Type B end-of-Phase 2 meeting minutes
- TSHA-102 in Rett syndrome for a period of time after the company provides Astellas access to certain clinical data from the female pediatric study
- Right of first offer related to any potential change in control of Taysha for a period of time upon receipt of the Rett data package
- One non-voting Board observer seat on the Taysha Board of Directors
Pricing of public offering of common stock
- On October 26, 2022, Taysha raised
$28.0 million in gross proceeds through an underwritten public offering of 14,000,000 shares of its common stock at a price to the public of$2.00 per share.
Anticipated Upcoming Milestones
- Regulatory update for TSHA-120 in GAN following receipt of formal meeting minutes from the Type B end-of-Phase 2 meeting with FDA expected in mid-January 2023
- Preliminary clinical safety and efficacy data for TSHA-102 from the entire first cohort of adult patients with Rett syndrome expected in H1 2023
- Initiation of Phase 1/2 trial for TSHA-102 in female pediatric patients with Rett syndrome in H1 2023
Third Quarter 2022 Financial Highlights
Research and Development (R&D) Expenses: Research and development expenses were
General and Administrative (G&A) Expenses: General and administrative expenses were
Net loss: Net loss for the three months ended September 30, 2022, was
Cash and cash equivalents: As of September 30, 2022, the Company had cash and cash equivalents of
Conference Call and Webcast Information
Taysha management will hold a conference call and webcast with slides today at 8:00 am ET / 7:00 am CT to review its financial and operating results and to provide a corporate update. The dial-in number for the conference call is 855-327-6837 (U.S./Canada) or 631-891-4304 (international). The conference ID for all callers is 10020611. The live webcast and replay may be accessed by visiting Taysha’s website at https://ir.tayshagtx.com/news-events/events-presentations. An archived version of the webcast will be available on the website for 30 days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the potential of our product candidates, including our preclinical product candidates, to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed, the potential market opportunity for these product candidates, our corporate growth plans, the forecast of our cash runway and the implementation and potential impacts of our strategic pipeline prioritization initiatives. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2021, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, both of which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.
Taysha Gene Therapies, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
(Unaudited)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | $ | 16,391 | $ | 39,528 | $ | 77,308 | $ | 94,025 | |||||||||
| General and administrative | 8,683 | 11,153 | 30,019 | 29,518 | |||||||||||||
| Total operating expenses | 25,074 | 50,681 | 107,327 | 123,543 | |||||||||||||
| Loss from operations | (25,074 | ) | (50,681 | ) | (107,327 | ) | (123,543 | ) | |||||||||
| Other income (expense): | |||||||||||||||||
| Interest income | 9 | 37 | 50 | 143 | |||||||||||||
| Interest expense | (1,241 | ) | (543 | ) | (3,002 | ) | (737 | ) | |||||||||
| Other expense | (1 | ) | - | (12 | ) | - | |||||||||||
| Total other expense, net | (1,233 | ) | (506 | ) | (2,964 | ) | (594 | ) | |||||||||
| Net loss | $ | (26,307 | ) | $ | (51,187 | ) | $ | (110,291 | ) | $ | (124,137 | ) | |||||
| Net loss per common share, basic and diluted | $ | (0.64 | ) | $ | (1.35 | ) | $ | (2.77 | ) | $ | (3.31 | ) | |||||
| Weighted average common shares outstanding, basic and diluted | 40,937,808 | 38,003,954 | 39,761,764 | 37,495,537 | |||||||||||||
Taysha Gene Therapies, Inc.
Condensed Consolidated Balance Sheet Data
(in thousands, except share and per share data)
(Unaudited)
| September 30, 2022 | December 31, 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 34,306 | $ | 149,103 | ||||
| Prepaid expenses and other current assets | 8,696 | 10,499 | ||||||
| Total current assets | 43,002 | 159,602 | ||||||
| Restricted cash | 2,637 | 2,637 | ||||||
| Deferred lease asset | 630 | 667 | ||||||
| Property, plant and equipment, net | 63,954 | 50,610 | ||||||
| Other non-current assets | 1,245 | 440 | ||||||
| Total assets | $ | 111,468 | $ | 213,956 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 15,521 | $ | 21,763 | ||||
| Accrued expenses and other current liabilities | 17,888 | 29,983 | ||||||
| Total current liabilities | 33,139 | 51,746 | ||||||
| Build-to-suit lease liability | 25,496 | 25,900 | ||||||
| Term Loan, net | 37,773 | 37,192 | ||||||
| Other non-current liabilities | 3,934 | 3,735 | ||||||
| Total liabilities | 100,342 | 118,573 | ||||||
| Stockholders' equity | ||||||||
| Preferred stock, | - | - | ||||||
| Common stock, | 1 | - | ||||||
| Additional paid-in capital | 357,065 | 331,032 | ||||||
| Accumulated deficit | (345,940 | ) | (235,649 | ) | ||||
| Total stockholders’ equity | 11,126 | 95,383 | ||||||
| Total liabilities and stockholders' equity | $ | 111,468 | $ | 213,956 | ||||
Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com
Media Contact:
Carolyn Hawley
Evoke Canale
carolyn.hawley@evokegroup.com
FAQ
What is the significance of Astellas Pharma's $50 million investment in Taysha (TSHA)?
When is Taysha expecting to provide updates on TSHA-120 for GAN?
What were Taysha's financial results for Q3 2022?
What clinical trials is Taysha planning for TSHA-102 in 2023?
